复方新诺明联合二线药物治疗耐多药结核病的临床疗效分析

摘要

Objective To investigate the effect of compound sulfamethoxazole(SMZ.Co) combined with second-line drugs in the treatment of multiple drug-resistant tuberculosis(MDR-TB).Methods Eighty-five cases of MDR-TB collected in this hospital from March 2014 to December 2016 were divided into the group A,B and C group.The C group underwent the conventional secondline anti-TB treatment,on this basis the group A and B were additionally added with 0.96 g and 0.48 g SMZ.Co respectively.The clinical curative effects(such as cough,phlegm,sputum bacterial negative conversion rate and X-rays) were compared among the three groups.Results Compared with C group,the cough and phlegm rates after continuous treatment for six months in the group A and B treated by combined use of SMZ.Co were significantly decreased,the difference was statistically significant(P＜0.05),while the sputum bacterial negative conversion rate,change of lesion focus and cavity,and treatment outcome rate had no statistical difference(P＞0.05).Conclusion The application of SMZ.Co combined with second-line drugs in the treatment of MDR-TB could effectively relieve the symptom of cough and phlegm.%目的 评价复方新诺明(SMZ.Co)对耐多药结核病(MDR-TB)的抗结核疗效.方法 收集该院2014年3月1日至2016年12月31日MDR-TB患者85例,分A、B、C3组.C组行常规二线抗结核治疗,在此基础上,A组增加0.96 g SMZ.Co,B组增加0.48 g SMZ.Co,比较3组患者的治疗效果(咳嗽、咳痰情况、痰菌转阴率、影像学检查及治疗转归情况等).结果 持续治疗6个月后,与C组相比,A、B组患者咳嗽、咳痰率明显下降,差异有统计学意义(P＜0.05),但痰菌阴转率、病灶、空洞的变化与治疗转归率比较差异无统计学意义(P＞0.05).结论 抗结核治疗方案中联合使用SMZ.Co可有效减轻MDR-TB患者咳嗽、咳痰等症状.